Connection

Solange Peters to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications Solange Peters has written about Antibodies, Monoclonal.
Solange Peters
Connection Strength
0.315
Antibodies, Monoclonal
  1. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017 Aug 20; 35(24):2781-2789.
    View in: PubMed
    Score: 0.174
  2. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 2019 01; 20(1):e54-e64.
    View in: PubMed
    Score: 0.048
  3. Immune Checkpoint Inhibitors in the Management of Lung Cancer. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:682-695.
    View in: PubMed
    Score: 0.046
  4. Genomic Features of Response to Combination Immunotherapy in Lung Cancer. Cancer Cell. 2018 05 14; 33(5):791-793.
    View in: PubMed
    Score: 0.046
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.